The NEURONET Knowledge Base brings together key information about the various projects of the Innovative Medicines Initiative (IMI) neurodegeneration (ND) portfolio. This comprehensive resource is an integral part of NEURONET’s endeavour to boost collaboration across the research portfolio by assisting in identifying gaps, multiplying the portfolio’s impact, and enhancing its visibility with related initiatives in Europe and worldwide.
As well as providing a summary overview of the IMI neurodegeneration research portfolio through its interactive dashboard, the NEURONET Knowledge Base includes links to over 500 publications and more than 380 publishable deliverable reports, acting as a one-stop shop to explore the diverse projects and outputs of the portfolio.
An “Asset Map” gives a comprehensive view of the different assets resulting from the projects, such as genetic datasets, clinical cohorts and data platforms. Furthermore, the Knowledge Base offers access to a regulatory, health technology assessment & payer engagement Decision Tool to help researchers identify the key processes and procedures for engagement with these stakeholders at key points in the development of an asset.
In addition to project and portfolio-related information, users can also access an agenda listing key upcoming scientific conferences and view a feed with the latest project-related news.
“The Knowledge Base sets the stage for future research tools to inform and shape the next generation of research and advancements in the neurodegeneration field.”
Associate Director, Clinical Scientist, Janssen Pharmaceutica NV, and NEURONET Project Leader.
“The NEURONET Knowledge Base tool intends to bring the “better together” concept to life and overcome the inherent fragmentation often found in a project-based research landscape.”
CEO SYNAPSE and NEURONET Coordinator.
Neuronet has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.
Any information on this website solely reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.